Vanguard reports 5.2% stake in Veracyte
Vanguard Capital Management reports beneficial ownership of 4,132,224 shares of Veracyte Inc, representing 5.20% of the class as of 03/31/2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Vanguard Capital Management reports beneficial ownership of 4,132,224 shares of Veracyte Inc, representing 5.20% of the class as of 03/31/2026. The filing shows Vanguard has sole power to dispose of 4,132,224 shares and sole voting power over 599,992 shares. The disclosure attributes ownership to Vanguard Capital Management and affiliated Vanguard entities; signature dated 04/30/2026.
Key Figures
Key Terms
Schedule 13G regulatory
beneficially owned financial
sole dispositive power regulatory
Investment Company Act of 1940 regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What stake does Vanguard Capital Management report in Veracyte (VCYT)?
As of what date is the Veracyte ownership reported by Vanguard?
Who at Vanguard signed the Schedule 13G for Veracyte?
AI-generated analysis. How Rhea-AI works. Not financial advice.